Agenus announces Phase II results from gastroesophageal cancer therapy

​Agenus has reported results from a Phase II trial, evaluating the combination of BOT, BAL, and agenT-797 alongside ramucirumab and paclitaxel, in advanced PD-1 refractory gastroesophageal adenocarcinoma patients.

The post Agenus announces Phase II results from gastroesophageal cancer therapy appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Bruker unveils MyGenius PRO diagnostics system
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Philips secures FDA clearance for Verida spectral CT system
First patient receives JANX014 dose in Janux’s trial for mCRPC
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us